Hemavant Sciences is a biopharmaceutical company that develops novel therapies for patients with rare blood disorders and cancers. They have an investigational drug product called RVT-2001 that is a potent, selective, and orally bioavailable small molecule modulator of SF3B, a component of the spliceosome commonly mutated in lower-risk (LR) MDS.
You can also compare their products with other competitors using the CB Insights Platform.
You can also compare their products with other competitors using the CB Insights Platform.
Location: United States, New York
Founded date: 2022